While targeted therapies against B-Raf proto-oncogene (BRAFV600) and its downstream target mitogen-activated protein kinase kinase 1/2 (MEK1/2) are beneficial for patients with BRAF mutant unresectable melanoma, acquired resistance remains a fundamental clinical challenge [1,2,3,4,5]. This evidence concerns the gene MAPK1 and melanoma.